ISO 16921-2:2026 PDF

Overview

ISO 16921-2:2026 – Biotechnology - Gene Delivery Systems - Part 2: Quantification Methods for Viral Vectors is an international standard published by ISO that outlines the minimum requirements and key considerations for quantifying viral vectors, specifically addressing both physical titer and associated activity measurements. This document establishes unified approaches for method selection, measurement processes, data analysis, and reporting-critical components for pharmaceutical, biotechnology, and research organizations engaged in gene therapy, vaccine development, and cellular therapies.

Viral vector quantification is crucial for ensuring the quality, consistency, and safety of gene delivery applications. Accurate determination of viral vector titers underpins productivity, regulatory compliance, and the reproducibility of advanced therapies and research.

Key Topics

• Physical Titer Measurement

  • Differentiates between direct particle counting (enumeration of individual viral particles) and indirect particle counting (estimation based on surrogate metrics such as nucleic acid or protein content).
  • Details relevant methods for quantifying viral vectors, including direct (e.g., electron microscopy, flow virometry, nanoparticle tracking analysis) and indirect approaches (e.g., ELISA capsid protein analysis, quantitative PCR, digital PCR, nucleic acid fluorescence, and absorbance).
  • Stresses the importance of reporting results in standardized units, such as particles/mL, capsids/mL, or genome copies/mL.

• Activity Assays

  • Describes functional assays for measuring the biological activity and infectivity of viral vectors.
  • Outlines methodologies such as transduction efficiency in target cells and assays for infectivity (e.g., plaque or focus formation).

• Assay Selection and Validation

  • Provides guidance on selecting a fit-for-purpose assay based on the specific gene delivery application.
  • Emphasizes the need for thorough sample preparation, controls, and qualification of assay methods and instruments.
  • Highlights requirements for method validation and verification to ensure traceability and reliability.

• Data Analysis and Reporting

  • Requires detailed data processing protocols and clear, thorough reporting of results, including method descriptions and units.
  • Advocates for adopting minimum information standards (e.g., MIQE guidelines for qPCR and dPCR).

• Purity and Quality Considerations

  • Explains the impact of impurities, such as free capsid proteins or host DNA, on measurement accuracy.
  • Recommends employing a matrix approach that combines multiple assays for a comprehensive quality assessment.

Applications

ISO 16921-2:2026 is applicable to organizations manufacturing, developing, or using viral vectors in a variety of biotechnology and clinical settings, including:

• Gene Therapy Development: Accurate viral vector titer quantification is crucial for dosing, safety, and efficacy in gene therapy applications.
• Vaccine Production: Ensures consistency and potency in viral vector-based vaccine platforms.
• Cell-based Therapies: Facilitates reliable engineering of cellular products deployed in immunotherapy or regenerative medicine.
• Basic Research: Provides consistency in gene delivery experiments across laboratories and global research teams.
• Quality Control and Regulatory Compliance: Supports adherence to regulatory requirements for product characterization and manufacturing consistency.

Related Standards

• ISO 16921-1 - Biotechnology - Gene Delivery Systems - Part 1: Vocabulary: Defines essential terms for gene delivery and viral vector work.
• ISO 20395 - Biotechnology - Requirements for Evaluating the Performance of Quantification Methods for Nucleic Acid Target Sequences - qPCR and dPCR: Provides methods for evaluating nucleic acid quantification, pertinent to indirect titer determination.

Practical Value

Adoption of ISO 16921-2:2026 standardizes viral vector quantification methods, facilitating global harmonization, robust quality control, and efficient technology transfer in biotechnology. It enables stakeholders to make informed decisions about viral vector production, assay selection, and product release, ultimately supporting the delivery of safe, effective gene therapies and biotechnological innovations.

Keywords: ISO 16921-2:2026, biotechnology standard, viral vector quantification, gene delivery systems, viral titer measurement, activity assays, method validation, gene therapy, vaccine production, dPCR, qPCR, ELISA.